Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 18.01.2022.

#ICYMI
#radiopharmaceutical
#oncology
#NOXXON
#CEO
#innovative
#biopharma
#drugdiscovery
#pharma
#cancer

Healthcare

@BIODeutschland shared
On Jan 13, 2022
RT @ITM_Radiopharma: Today we announced a cooperation with @HelmholtzMunich for the clinical development of the #radiopharmaceutical therapy candidate LuCaFab (ITM-31) to treat malignant brain tumors. We look forward to supporting the planned dose-escalation phase I trial. https://t.co/ENEBrsly4d https://t.co/SI6qhZnvUV
Open
ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

Investigator-initiated multicenter Phase I study in glioblastoma with CA XII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of …

@daphnezohar shared
On Jan 16, 2022
My colleague Bharatt Chowrira is joining @ldtimmerman & some other terrific biotech executives Eg @drsam to raise money for a terrific cause @fredhutch @FredHutchGO to support basic research in #oncology #cancer Join me in supporting this important mission https://t.co/TdDD5isqhy
Open
Welcome to Bharatt's Climb to Fight Cancer

Welcome to Bharatt's Climb to Fight Cancer

I am thrilled to be joining the Fred Hutch’s Climb to Fight Cancer initiative -- a trek to the Mt. Having worked in biotech for almost three decades, I am a big believer in the …

@BIODeutschland shared
On Jan 17, 2022
RT @noxxon_pharma: #NOXXON thanking our shareholders for their constant support and belief in our highly innovative approach targeting TME to treat difficult to treat cancers. Read our #CEO message reflecting on the progress we made last year and strategies for the new year:https://t.co/c5DSmJyCtx https://t.co/PD7eCbvCMX
Open
CEO Message

CEO Message

The company has made meaningful progress towards our goal of transforming the way cancer is treated through our highly innovative approach of targeting the tumor microenvironment …

@ldtimmerman shared
On Jan 17, 2022
The Everest Base Camp trek has been more than 2 years in the making. Proud of this team, this group of steadfast sponsors, and the outstanding scientists @fredhutch. For more on the trek, including some cool photos 👇https://t.co/fiaHkhl8iW https://t.co/LEefX6Wkis
Open
The Everest Base Camp Climb to Fight Cancer

The Everest Base Camp Climb to Fight Cancer

The Everest Base Camp Climb to Fight Cancer Science is at a moment of tremendous possibility. Support Fred Hutch by sponsoring a team of biotech leaders on a trek to Everest Base …

@BioPharmaMike shared
On Jan 17, 2022
RT @ClarivateHealth: #ICYMI >> Clarivate identifies seven potential blockbuster drugs in annual Drugs to Watch report, to realize improved patient outcomes and finance the next generation of #innovative medicines. https://t.co/pafeNaP0iV #drugstowatch2022 #pharma #biopharma #drugdiscovery https://t.co/pO8Zg5WZMU
Open
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer’s, diabetes and asthma Report also examines key therapeutic ...

@SWLifeSciences shared
On Jan 11, 2022
Biotech Co. Partners With Life Sciences Firms: https://t.co/Ni21IpI4hO Wedbush has an Outperform rating and a $41 per share price target on 2seventy bio inc. $TSVT #biotech #stocks https://t.co/8VG7xVIYMV
Open
Biotech Co. Partners With Life Sciences Firms Research Report

Biotech Co. Partners With Life Sciences Firms Research Report

2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

@TuftsCSDD shared
On Jan 13, 2022
What past participants are saying about our annual Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation: Invest in the most impactful 24 hours of your pharmaceutical career! For more information, please visit: https://t.co/HzIC5hfxkU https://t.co/U3cyRV4YZP
Open
Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation

Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation

About this Course 49th Annual Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation Tufts CSDD’s Postgraduate Course in Clinical Pharmacology, Drug …

@eupatients shared
On Jan 12, 2022
RT @EatrisEric: As part of the #EATRISPlus project, we're looking for independent experts to form a 'Regulatory Task Force'. The call is now open for experts in the field. 👉 Find out more about the call here: https://t.co/10rWnXuRfk #PersonalisedMedicine #horizon2020 #H2020 #EU_RI #EU_RIs https://t.co/zWmPRVxWX2
Open
Open Call for Regulatory Experts

Open Call for Regulatory Experts

One task of the EATRIS-Plus project is to expand catalog of services by setting up an EATRIS Regulatory Task Force composed by a maximum of ten EATRIS Regulatory Experts. Foreseen …